- Home
- NRT vs PRLD Comparison
NRT vs PRLD Comparison
Compare NRT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRT | PRLD |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 69.1M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRT | PRLD |
|---|---|---|
| Price | $8.69 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 110.6K | ★ 329.7K |
| Earning Date | 04-28-2026 | 06-17-2026 |
| Dividend Yield | ★ 9.00% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ 0.21 | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $42.86 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $4.00 | $0.61 |
| 52 Week High | $10.49 | $4.19 |
Technical Indicators
Market Signals| Indicator | NRT | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 60.22 |
| Support Level | $8.50 | $1.02 |
| Resistance Level | $9.46 | $4.19 |
| Average True Range (ATR) | 0.58 | 0.35 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 31.05 | 56.16 |
Price Performance
Historical ComparisonAbout NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.